Phase IB study of PKC412, an oral FLT3 kinase inhibito in sequential and simultaneous combination with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML
Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G, Cortes J, Kantarjian H, DeAngelo DJ, Yu R, Xhang L, Cohen PS, Wang Y, Phillips P, Giles F. Phase IB study of PKC412, an oral FLT3 kinase inhibito in sequential and simultaneous combination with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML. Blood. 2005; 106:121a.